Skip to Content

Posts tagged with "Cancer"

  • Cancer

    More on Penn’s T-Cell Therapy

    There’s more news on the T-cell therapy work that I wrote about here and here. The New York Times has an update, and the news continues to be encouraging. So far about a dozen leukemia patients have been treated, and while not everyone has responded, there have been several dramatic remissions. Considering that every candidate… Read More
  • Cancer

    A Good Example of Phenotypic Screening

    I like to highlight phenotypic screening efforts here sometimes, because there’s evidence that they can lead to drugs at a higher-than-usual rate. And who couldn’t use some of that? Here’s a new example from a team at the Broad Institute. They’re looking at the very popular idea of “cancer stem cells” (CSCs), a p… Read More
  • Cancer

    JQ1: Giving Up a Fortune?

    The Atlantic is out with a list of “Brave Thinkers”, and one of them is Jay Bradner at Harvard Medical School. He’s on there for JQ1, a small-molecule bromodomain ligand that was reported in 2010. (I note, in passing, that once again nomenclature has come to the opposite of our rescue, since bromodomains have absolutely… Read More
  • Cancer

    The Onion on Oncology Research

    I’d say they have it pretty close to reality: “. . .a new Mayo Clinic study with widespread implications for the treatment and potential cure of the disease has found that the malignant growths have begun cruelly mocking researchers. 
 The findings—published this week in a rambling, expletive-laden 8,000-word article in The Journal… Read More
  • Cancer

    Texas And Its Cancer Funding

    Texas put up a lot of money a few years ago for cancer research. “A lot”, in this case, means three billion, to be awarded by the Cancer Prevention Research Institute of Texas (CPRIT). This is where the money came to get K. C. Nicolaou for Rice University, for example, and much other research spending… Read More
  • Cancer

    IGFR Therapies Wipe Out. And They’re Not Alone.

    Here’s a look at something that doesn’t make many headlines: the apparent failure of an entire class of potential drugs. The insulin-like growth factor 1 receptor (IGF-1R) has been targeted for years now, from a number of different angles. There have been several antibodies tried against it, and companies have also tried small molecule… Read More
  • Cancer

    A Lovely Petite Compound

    I can’t resist pointing out this compound, which recently showed up in J. Med. Chem.. Now, that’s a Bcl-2/Bcl-xl inhibitor, the star of the protein-protein interaction world, and there’s probably never going to be a nice-looking compound that does the job in that system. The interacting surfaces are too wide and too shallow; it… Read More
  • Cancer

    CNN’s Cure for Cancer

    I’ve been meaning to write something about the M.D. Anderson announcement of “Moon Shot” programs for cancer therapies. Mostly something about how I’m very glad that they’re spending a lot of time and money on this, because there are a lot of good people there, but also about how I truly hate the “Moon Shot”… Read More
  • Cancer

    Geron, And The Risk of Cancer Therapies

    Geron’s telomerase inhibitor compound, imetalstat, showed a lot of interesting results in vitro, and has been in Phase II trials all this year. Until now. The company announced this morning that the interim results of their breast-cancer trial are so unpromising that it’s been halted, and that lung cancer data aren’t looking good… Read More
  • Cancer

    Making Tumor Cells More Vigorous Through. . .Chemotherapy?

    Here’s some food for thought: in some cases, chemotherapy may actually accelerate the growth of tumor cells. This study has found that noncancerous cells (which are also affected, to various degrees, by most chemotherapy agents) can secrete Wnt16B in response to treatment, and that this protein is taken up by nearby tumor cells. And that̵… Read More
...202122...